AstraZeneca (AZN) to Release Quarterly Earnings on Tuesday

AstraZeneca (NASDAQ:AZN) is expected to be announcing its Q1 2025 earnings results before the market opens on Tuesday, April 29th. Analysts expect AstraZeneca to post earnings of $1.10 per share and revenue of $13.71 billion for the quarter.

AstraZeneca (NASDAQ:AZN) last posted its earnings results on Thursday, February 6th. The company reported $1.05 EPS for the quarter, missing analysts’ consensus estimates of $1.10 by ($0.05). AstraZeneca had a net margin of 13.01% and a return on equity of 32.23%. On average, analysts expect AstraZeneca to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.

AstraZeneca Price Performance

Shares of AZN opened at $69.57 on Monday. The stock has a market capitalization of $215.75 billion, a PE ratio of 30.78, a PEG ratio of 1.42 and a beta of 0.49. The company has a 50 day moving average price of $72.33 and a 200-day moving average price of $70.16. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.74 and a current ratio of 0.93. AstraZeneca has a fifty-two week low of $61.24 and a fifty-two week high of $87.68.

AstraZeneca Increases Dividend

The business also recently announced a semi-annual dividend, which was paid on Monday, March 24th. Shareholders of record on Friday, February 21st were issued a dividend of $1.03 per share. The ex-dividend date was Friday, February 21st. This represents a yield of 2%. This is a positive change from AstraZeneca’s previous semi-annual dividend of $0.49. AstraZeneca’s dividend payout ratio is currently 91.15%.

Institutional Trading of AstraZeneca

An institutional investor recently raised its position in AstraZeneca stock. Brighton Jones LLC increased its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 93.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,782 shares of the company’s stock after buying an additional 2,789 shares during the quarter. Brighton Jones LLC’s holdings in AstraZeneca were worth $379,000 as of its most recent SEC filing. 20.35% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. UBS Group raised AstraZeneca from a “neutral” rating to a “buy” rating in a research report on Thursday, February 13th. Morgan Stanley initiated coverage on shares of AstraZeneca in a research report on Wednesday, February 12th. They set an “overweight” rating for the company. Finally, BNP Paribas initiated coverage on shares of AstraZeneca in a research report on Tuesday, April 15th. They issued an “outperform” rating and a $75.00 price objective on the stock. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, AstraZeneca currently has a consensus rating of “Buy” and a consensus target price of $88.00.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.